← TrialMatch
HomeTrials

The Impact of Phosphate Metabolism on Healthy Aging

Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-

Condition(s)Hypophosphatemia, Rickets, Hypercalciuria, XLH, HHRH
StatusRecruiting
PhaseEARLY_Phase 1
Study typeInterventional
SummaryDetermine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).
Who can participateInclusion Criteria: * Children above the age of 13 years * Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH) * Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data * Be willing and able to complete all aspects of the study * Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator). Exclusion Criteria: * Subjects will be excluded, if they are children younger than age 13 years * Subjects that have other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, gastrointestinal disorders, and malignancy), * Subjects th
Ages13 Years
SexAll
Lead sponsorYale University
LocationsNew Haven, Connecticut, United States
Start date2019-01-01
NCT IDNCT03771105
Official listinghttps://clinicaltrials.gov/study/NCT03771105

🔍 Search all trials →